Introduction {#S0001}
============

*Pseudomonas* spp. infections are problematic due to their ability to resist most classes of antibiotics. Few studies have been published regarding the prevalence of *P. aeruginosa* and its resistance to quinolones in the Kingdom of Saudi Arabia (KSA). Related to this, there is a substantial problem in intensive care units (ICU) among patients infected by multi-drug resistant (MDR) *Pseudomonas* isolates, reviewed elsewhere.[@CIT0001] Infections with MDR *Pseudomonas* lead to increased healthcare costs, longer hospital stays, and increased mortality rates.

Fluoroquinolones are among the most effective antibiotics against *Pseudomonas* spp. However, *Pseudomonas* has acquired several resistance mechanisms against several different types of antibiotics including quinolones. The activity and spectrum of the newer quinolones are much higher than older drug generations with increased microbial resistance observed for the lower generations.[@CIT0002] There are four known quinolone resistance mechanisms that work separately or in combination in *Pseudomonas* resulting in varying degrees of resistance, ranging from reduced susceptibility to clinically relevant resistance. These mechanisms may be chromosomally- or plasmid-mediated.[@CIT0003]

Chromosomal resistance to quinolones may occur due to target site mutation; ie, alterations in the target enzyme (DNA gyrase and/or DNA topoisomerase IV), alteration in membrane permeability and active efflux.[@CIT0004],[@CIT0005] The short mutated DNA sequence located in the *gyrase* and *topoisomerase IV* genes are responsible for fluoroquinolone resistance; and is known as the quinolone resistance-determining region (QRDR).[@CIT0006],[@CIT0007] In addition to the role of chromosomally-mediated resistance to quinolones, plasmids also play a pivotal role in resistance to quinolones. The term "resistance" in the context of plasmid-mediated quinolone resistance (PMQR) is used to refer to any increase in MIC, rather than an increase above a susceptibility breakpoint, as reviewed elsewhere.[@CIT0008],[@CIT0009] PMQR is more important in the horizontal spread of resistance between different isolates and different species further complicating the issue of microbial drug resistance. PMQR is mediated mainly by the quinolone resistance (*qnr*) genes. Three mechanisms are responsible for PMQR: target alteration by *qnr* gene products, drug modification by the aminoglycoside acetyltransferase "AAC(6′)-Ib-cr"; that is capable of reducing ciprofloxacin activity, and acquiring an efflux pump mechanism mediated by two reported quinolone efflux pumps known as olaquindox (OqxAB) and the QepA quinolone efflux plasmid.[@CIT0009],[@CIT0010]

Several reports examined the prevalence of quinolone resistance in the KSA and showed that it is increasing.[@CIT0011]--[@CIT0018] However, none of these studies were performed in the Taif area, which is located in the western part of the KSA. Importantly, very little is known about the mechanisms of quinolone resistance among *Pseudomonas* spp. in the KSA. The main objective of this study was to identify the potential genes that confer PMQR mechanisms among clinical isolates of *Pseudomonas* spp. and determine the clonal relatedness between quinolone-resistant isolates by ERIC-PCR. This study shows that PMQR among clinical *Pseudomonas* isolates from Taif, KSA, is mainly mediated by *qnrD, qnrS*, and *aac(6´)-Ib-cr*.

Subjects and methods {#S0002}
====================

Bacterial isolation and identification {#S0002-S2001}
--------------------------------------

The *Pseudomonas* spp. isolates included in this study were collected from December 2016 to April 2017. They were isolated as a part of routine hospital laboratory procedures and were further identified and confirmed in the laboratory. The study protocol was approved by Taif University Research Ethics Committee (approval \#38-35-0021). Ninety-two non-duplicate non-consecutive clinical isolates of *Pseudomonas* spp. were recovered from 92 cases. Of these cases, 56 and 36 were male (60.9%) or female (39.1%), respectively, with ages ranging between two months and 102 years, with an average age of 53.0±25.2 years. These patients were admitted to or attended different medical departments at a tertiary care hospital in Taif, KSA. The clinical isolates were recovered from different clinical specimens, namely, axillary swab (*n*=1), bile (*n*=4), blood (*n*=7), catheter tip (*n*=4), eye swab (n=3), peritoneal fluid (n=5), sputum (n=30), tracheal aspirate (n=2), urine (*n*=20), vaginal swab (n=2), and wound swab (*n*=14).

All strains were isolated primarily on MacConkey's agar (Oxoid, UK) and blood agar and were then purified on cetrimide agar (Scharlu, Spain). Genus level identification was determined by amplification of the *algD* gene using the primers listed in [Table 1](#T0001){ref-type="table"} (Macrogen, Geumcheon-gu, Seoul, Korea) and a Master cycler® personal PCR machine (Eppendorf, California, USA). Species level identification of the isolates was determined by Vitek (Biomeriux, France).Table 1Primer sets and PCR cycling conditions used for genotyping and amplification of genes encoding quinolone resistancePrimerSequenceGeneAmplification conditionsAmplicon size (bp)Reference**ERIC-1RR**: AACCCACGATGTGGGTAGC-Initial denaturation at 95 °C for 15 min then 35 cycles of 95 °C for 1 min, 40 °C for 1min and 72 °C for 5 mins and one cycle of final elongation at 72 °C-[@CIT0039]**VICF**: TTCCCTCGCAGAGAAAACATC\
**R**: CCTGGTTGATCAGGTCGATCT***algD GDP***Initial denaturation at 95 °C for 15 min then 30 cycles of 95 °C for 1 min, 58 °C for 1min and 72 °C for 5 mins and one cycle of final elongation at 72 °C520[@CIT0040]**QnrAF**: AGAGGATTTCTCACGCCAGG\
**R**: TGCCAGGCACAGATCTTGAC***qnrA***Initial denaturation at 95 °C for 15 min, then 30 cycles of 95 °C for 1 min, 55 °C for 1 min, and 72 °C for 5 mins, and one cycle of final elongation at 72 °C580[@CIT0041]**QnrBF**: GGCATTGAAATTCGCCACTG\
**R**: TTTGCTGCTCGCCAGTCGAA***qnrB***263[@CIT0041]**QnrD**F: CGAGATCAATTTACGGGGAATA\
R: AACAAGCTGAAGCGCCTG***qnrD***Initial denaturation at 95 °C for 15 min, then 30 cycles of 95 °C for 1 min, 56 °C for 1 min, and 72 °C for 5 min, and one cycle of final elongation at 72∘C533[@CIT0042]**QnrSF**: GCAAGTTCATTGAACAGGGT\
**R**: TCTAAACCGTCGAGTTCGGCG***qnrS***Initial denaturation at 95 °C for 15 min then 30 cycles of 95 °C for 1 min, 66.7 °C for 1min and 72 °C for 5 min and one cycle of final elongation at 72 °C428[@CIT0041]**Acc(6ʹ)-Ib-crF**: TTGCGATGCTCTATGAGTGGCTA\
**R**: CTCGAATGCCTGGCGTGTTT***acc(6ʹ)Ib-cr***Initial denaturation at 95 °C for 15 min then 30 cycles of 95 °C for 1 min, 63 °C for 1min and 72 °C for 5 min and one cycle of final elongation at 72 °C482[@CIT0043]**Qep**F: AACTGCTTGAGCCCGTAGAT\
R: GTCTACGCCATGGACCTCAC***qepA***Initial denaturation at 95 °C for 15 min, then 30 cycles of 95 °C for 1 min, 55 °C for 1 min, and 72 °C for 5 min, and one cycle of final elongation at 72 °C596[@CIT0044][^1]

Antimicrobial susceptibility testing {#S0002-S2002}
------------------------------------

All bacterial isolates were subjected to antimicrobial susceptibility testing by the broth microdilution method using cation modified Mueller-Hinton broth (Oxoid, UK) in 96 well microtiter plates. Twelve different dilutions of each quinolone were tested by the two-fold dilution method (concentrations tested ranged from 1,024 μg/ml to 0.5 μg/ml). Seven quinolone antibiotics, representing the four generations of quinolones, were tested, which included nalidixic acid (NAL), representing the first generation; ciprofloxacin (CIP), norfloxacin (NOR), and ofloxacin (OFL), representing the second generation; levofloxacin (LEV), representing the third generation, and gemifloxacin (GEM) and moxifloxacin (MOX), representing the fourth generation (all from Sigma-Aldrich, USA). *P. aeruginosa* ATCC27853 was used as a quality control strain. Results were interpreted according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI).[@CIT0019] Since the CLSI guidelines do not specify a breakpoint for gemifloxacin, its breakpoint was based on the values proposed by the British Society for Antimicrobial Chemotherapy (≤0.5 mg/L for susceptible, and ≥1 mg/L for resistant).[@CIT0020] Also, moxifloxacin data were interpreted based on European Committee on Antimicrobial Susceptibility Testing (EUCAST) e-coff and modal MIC, which, for *Pseudomonas*, are 4 μg/ml and 1 μg/ml, respectively.[@CIT0021]

Preparation of DNA templates for PCR testing {#S0002-S2003}
--------------------------------------------

DNA was extracted as previously described.[@CIT0022] PCR reactions were performed in a final reaction volume of 20µl. Reactions contained 4µl of extracted DNA, 4 µl of 5x master mix (HOT FIREPol® Blend Master Mix, Solis BioDyne, Tartu, Estonia), 0.6 µl of forward primer (10 pmol/μl), 0.6 µl of reverse primer (10 pmol/μl) and 10.8 µl distilled water.

Molecular detection of plasmid-mediated quinolone resistance {#S0002-S2004}
------------------------------------------------------------

Clinical *Pseudomonas* isolates that were resistant to any of the tested quinolones were screened for six quinolone resistance genes: *qnrA, qnrB, qnrD*, and *qnrS*, the quinolone efflux gene *qep*A, and the quinolone modifying enzyme gene; *acc(6ʹ)-1b-cr*. PCR primers (Macrogen) and cycling conditions are listed in [Table 1](#T0001){ref-type="table"}.

Genotyping and fingerprint analysis of clinical isolates {#S0002-S2005}
--------------------------------------------------------

Clonal relatedness between quinolone-resistant clinical isolates of *Pseudomonas* was determined by enterobacterial repetitive intergenic consensus (ERIC)-PCR. The primer was obtained from Macrogen and PCR amplification was conducted according to the cycling conditions described in [Table 1](#T0001){ref-type="table"}. Banding patterns generated by ERIC-PCR were analyzed using BioNumerics 7.5 software (Applied Maths, Kortrijk, Belgium). PCR fingerprint profiles were analyzed using Dice (similarity) coefficient. Cluster analysis was performed as previously described,[@CIT0023] based on the unweighted pair group method with arithmetic averages (UPGMA) at a position tolerance of 0.15.

Results {#S0003}
=======

Isolation and identification of clinical Pseudomonas isolates {#S0003-S2001}
-------------------------------------------------------------

All recovered isolates were found to be related to the genus *Pseudomonas* based on amplification of the *algD* gene (data not shown). Phenotypic identification at the species level using the Vitek® 2 GN ID card revealed that 83 of the 92 isolates (90.2%) were *P. aeruginosa*, three isolates each were *P. putida*, and *P. fluorescence* (3.3% each), and there was one isolate (1.1%) each of *P. luteola, P. stutzuri*, and *P. oryzihabitans*.

Antimicrobial susceptibility of Pseudomonas isolates to different quinolones {#S0003-S2002}
----------------------------------------------------------------------------

The first step in examining the mechanisms of quinolone resistance was to test the susceptibility of the *Pseudomonas* isolates to seven selected quinolones by the microbroth dilution method. Susceptibility testing revealed that 39 isolates (42.4%) were highly resistant to at least one of the tested quinolones, while the remaining isolates were susceptible to all quinolones. The 39 resistant isolates were recovered from different clinical specimens, namely, axillary swab (*n*=1), bile (*n*=2), blood (*n*=4), catheter tip (*n*=1), sputum (n=20), urine (*n*=6), and wound (*n*=5).

Nalidixic acid was the least effective quinolone against *Pseudomonas* spp.; 41.3% (38/92) of the isolates were resistant. Gemifloxacin, ciprofloxacin, and levofloxacin were the most effective agents, in which 28.3% (26/92), 35.9%, and 35.9% (33/92) of the isolates were resistant, respectively ([Table 2](#T0002){ref-type="table"}). A similar resistance rate (37.0%; 34 of the 92 isolates) was observed for norfloxacin and ofloxacin. The rate of moxifloxacin resistance was 39.1% (33/92).Table 2Percentage of resistance of clinical Pseudomonas isolates to different quinolonesAntimicrobial agentMIC RangeMIC~50~MIC~90~No. of resistant isolates (%)µg/mlµg/mlNalidixic acid16:\>1024\>1024\>102438 (41.3)Ciprofloxacin≤0.5:128\>16\>6433 (35.9)Norfloxacin≤0.5:\>1024\>16\>6434 (37.0)Ofloxacin≤0.5:512\>64\>12834 (37.0)Gemifloxacin≤0.5:256\>32\>6426 (28.3)Levofloxacin≤0.5:256\>32\>6433 (35.9)Moxifloxacin1:512\>64\>6436 (39.1)

The MIC~50~ and MIC~90~ of the seven tested quinolones are shown in [Table 2](#T0002){ref-type="table"}. Nalidixic acid had the highest MIC~50~ and MIC~90~ (\>1024 μg/ml). Ciprofloxacin and norfloxacin had the lowest MIC~50~ and MIC~90~ (\>16 μg/ml and \> 64μg/ml, respectively).

Based on the quinolone resistance data, the 39 quinolone-resistant *Pseudomonas* isolates were classified into seven different quinolone-resistant biotypes, as shown in [Table 3](#T0003){ref-type="table"}. The most common biotype was resistant to all the tested quinolones, corresponding to 66.7% of the isolates (26/39). The second most common quinolone-resistant biotype was resistant to six quinolones: NAL, CIP, NOR, OFL, LEV, and MOX, corresponding to 15.4% of the isolates (6/39). The remaining biotypes are shown in [Table 3](#T0003){ref-type="table"}.Table 3Resistance pattern and genetic profile of quinolone resistant *Pseudomonas* spp. isolatesIsolate No.Quinolone resistance profileNo. of quinolones with resistancePMQR profileNo. of detected PMQR genesPs1NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps3NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps4NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps5NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps6NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps7NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps8NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps9NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD2Ps10NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps11NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps12NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrS2Pp13NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps14NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps15NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps16NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps17NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps18NAL, CIP, NOR, OFL, LEV, MOX6-0Ps19NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrS2Ps20NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrS2Ps21NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps23NAL, CIP, NOR, OFL, LEV, MOX6acc(6ʹ)-Ib-cr1Ps24NAL, CIP, NOR, OFL, GEM, LEV, MOX6qnrD1Ps25NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps26NAL, CIP, NOR, OFL, LEV, MOX7qnrD, qnrS2Ps27NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps28NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps29NAL, CIP, NOR, OFL, LEV, MOX6acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps30NAL, CIP, NOR, OFL, LEV, MOX6qnrD, qnrS2Ps31NAL1qnrS1Ps32NAL1qnrD1Ps33NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps34NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD2Ps35NAL, CIP, NOR, OFL, GEM, LEV, MOX7acc(6ʹ)-Ib-cr, qnrD, qnrS3Pp36NAL, MOX2qnrD, qnrS2Ps37NAL, MOX2qnrD, qnrS2Ps38NAL, CIP, NOR, OFL, LEV, MOX6acc(6ʹ)-Ib-cr, qnrD, qnrS3Ps39NAL, NOR, OFL, LEV, MOX5qnrS1Ps40NAL, CIP, NOR, OFL, MOX5qnrD1Ps41NOR1-0[^2]

Detection of PMQR genes among the quinolone-resistant Pseudomonas isolates {#S0003-S2003}
--------------------------------------------------------------------------

PCR was carried out to screen for the presence of the PMQR genes (*qnrA, qnrB, qnrD, qnrS, qepA*, and *aac(6´)-Ib-cr*) among the 39 quinolone-resistant *Pseudomonas* isolates. As shown in [Table 3](#T0003){ref-type="table"}, *qnrD, qnrS*, and *aac(6´)-Ib-cr* were found in 31, 31 (79.5% each), and 28 (71.8%) of the 39 isolates, respectively. *qnrA, qnrB* and *qep*A were not detected and two isolates did not harbor any of the six tested genes. Additionally, *qnrD, qnrS* and *aac(6´)-Ib-cr* were collectively found in 22 of the isolates (56.4%). In addition, four of the isolates (10.2%) contained both *qnrD*, and *qnrS*. On the other hand, 5.1% (2/39) of the isolates did not contain any of the six tested PMQR genes ([Table 3](#T0003){ref-type="table"}). The average number of PMQR genes detected among the resistant isolates was 2.3±0.9.

Fingerprint pattern analysis {#S0003-S2004}
----------------------------

Clonal relatedness of the 39 quinolone-resistant clinical isolates of *Pseudomonas* spp. was determined by ERIC-PCR. Representative ERIC-PCR results are shown in [Figure 1](#F0001){ref-type="fig"}. The UPGMA dendrogram at 85% similarity ([Figure 2](#F0002){ref-type="fig"}) demonstrated that the 39 *Pseudomonas* isolates corresponded to 38 different ERIC profiles in which only two isolates (Pa16 and Pa17) had identical profiles. The dendrogram classified the 39 isolates into two main phylogenetic groups: phylogenetic group A (PGA) and phylogenetic group B (PGB). The majority of the 39 isolates (94.8%) were categorized in PGB ([Figure 2](#F0002){ref-type="fig"}). PGB was further divided into three sub-phylogenetic groups: PGB1.1, PGB1.2, and PGB2. The major sub-phylogenetic group of PGB was PGB1.2, in which 59.5% (22/37) of the isolates clustered.Figure 1A representative example of ERIC-PCR pattern for clinical *Pseudomonas* isolates. There are five isolates on either side of the ladder (middle lane) on the gel.Figure 2Phylogenetic dendrogram analysis of quinolone-resistant *Pseudomonas* isolates by dice similarity coefficient clustering using ERIC-PCR based on the unweighted pair group method with arithmetic averages (UPGMA) at a position tolerance at 0.15. The banding pattern generated by ERIC-PCR was analyzed using BioNumerics software. The PCR fingerprint profile was analyzed using Dice (similarity) coefficient. Cluster analysis was performed based on UPGMA at a position tolerance of 0.15.**Abbreviations:** PGA, phylogenetic group A; PGB, phylogenetic group B.

Discussion {#S0004}
==========

In this study, 92 different *Pseudomonas* isolates were collected from patients in a tertiary care hospital in Taif, KSA. Thirty-nine of the isolates (42.4%) were resistant to at least one quinolone. Of the seven tested quinolones, gemifloxacin was the most effective, as only 28.3% of isolates were resistant. The rate of resistance to the other six tested quinolones was ≥35.9%. The most common quinolone resistance biotype was resistant to the seven tested quinolones (66.7%; 26/39). The high fluoroquinolone resistance rate in the current study prompted us to investigate the prevalence of the PMQR genes among the quinolone-resistant isolates. *qnr*D, and *qnr*S were found in 79.5% of the isolates (31/39) and *aac(6´)-Ib-cr* was found in 71.8% of the resistant isolates (28/39). *qnr*A, *qnr*B, and *qep*A were not detected in any of the isolates. Two isolates did not harbor any of the six tested genes. Interestingly, *qnr*D, *qnr*S, and *aac(6´)-Ib-cr* were found together in 22 of the 39 quinolone-resistant isolates (56.4%). In addition, the isolates showed 38 different ERIC profiles and only two isolates (Pa16 and Pa17) had an identical profile. Several aspects of these data deserve further discussion.

First, antibiotic resistance represents a major health care problem due to increased mortality and longer hospital stays, which increase the cost of healthcare service provided to patients. In view of the growing number of patients with nosocomial infections worldwide, including the KSA, and the limited number of treatment options for infections caused by *Pseudomonas* spp., patients and their doctors are searching for effective therapies. This is the first study to address the possible role of PMQR among *Pseudomonas* spp. in the KSA. This study is also of interest since, to the best of our knowledge, no other studies have evaluated quinolone resistance in the Taif area, located in the western part of the KSA. The prevalence of quinolone resistance among the *Pseudomonas* spp. isolated in Taif during the study period showed that approximately one third or more of the isolates were resistant to at least one quinolone, which is a high proportion that limits the usage of fluoroquinolones to treat patients infected with *Pseudomonas* spp.

Second, 39 of the isolates (42.4%) were resistant to at least one quinolone. Gemifloxacin was the most effective quinolone (28.3% resistance rate), while the resistance rate to the other six quinolones was ≥35.9%. These data are consistent with previous findings that showed an escalation in quinolone resistance over time in the KSA.[@CIT0011]--[@CIT0018] In this regard, the MIC~50~ and MIC~90~ of nalidixic acid were the highest among the tested quinolones, both measuring \>1,024 μg/ml. The nalidixic acid resistance rate recorded herein is relatively low (41.3%) as compared to other reports from the KSA,[@CIT0018],[@CIT0024] suggesting that limiting the use of a certain agent can lead to a decrease in the resistance rate. Resistance to all seven tested quinolones was the most common quinolone resistance biotype, corresponding to two-thirds (26/39) of the isolates. This suggests a horizontal transfer of plasmid-mediated resistance genes between different strains.

Third, the genetic basis of PMQR among the isolated *Pseudomonas* spp. was determined by screening for three different resistance mechanisms using PCR, including efflux mechanisms (*qep*A), modifying enzymes (*aac(6´)-Ib-cr*), and *qnr* genes (*qnr*A, *qnr*B, *qnr*D, and *qnr*S). *qnr*D, *qnr*S, and *aac(6´)-Ib-cr* were found in 31, 31 (79.5% each) and 28 (71.8%) of the 39 isolates, respectively, while *qnr*A, *qnr*B, and *qep*A were not detected. A similar finding regarding *qep*A was recently reported in a Turkish study.[@CIT0025] Also, *qnr*D, *qnr*S, and *aac(6´)-Ib-cr* were found together in 22 (56.4%) of the 39 quinolone-resistant isolates. These data and those presented in [Table 3](#T0003){ref-type="table"} suggest that these clinical *Pseudomonas* isolates possess several resistance mechanisms that can lead to quinolone resistance. In contrast, two isolates did not harbor any of the six tested genes, suggesting that chromosomal resistance or another PMQR gene(s) not-investigated in this study may encode the mechanisms responsible for quinolone resistance in these two isolates. A recent study in Egypt reported the presence of *qnrB*, and *qnrS* in 1.8% and 2.7% of *Pseudomonas* isolates, respectively. The authors did not find any other PMQR genes among the isolates.[@CIT0026] Although the general findings of this study are similar to our findings, the frequency of PMQR gene detection is much lower than in our study. Another study in China reported the detection of *qnrA* in only one ciprofloxacin resistant isolate.[@CIT0027] Also, *qnrS*, and *aac(6´)-Ib-cr* were found in only one (2.6%) of 38 *P. aeruginosa* isolates in Brazil.[@CIT0028] On the other hand, *qnrB* was found in 20% of *Pseudomonas* isolates in a study conducted in Poland,[@CIT0029] while *qnrS* was found in 21% of the isolates in a study conducted in Iraq.[@CIT0030] These rates are similar to our findings. Together, these data show that PMQR genes have been found worldwide in *Pseudomonas* isolates at different frequencies.

Fourth, different typing methods are used in epidemiologic studies of infectious agents (including *Pseudomonas*), which include phage typing, serologic testing, pyocyanin typing, and DNA fingerprinting. However, no system is universally accepted.[@CIT0031] ERIC--PCR, which is based on amplification of highly conserved 126-bp non-coding regions, is used for molecular typing of different microorganisms.[@CIT0032] These conserved regions consist of imperfect palindromes that occur in multiple copies in the genomes of enteric bacteria and vibrios.[@CIT0033]--[@CIT0036] Molecular typing using ERIC-PCR provides more discriminative species-specific DNA patterns) that cannot be detected by pulsed-field gel electrophoresis.[@CIT0037],[@CIT0038] In our study, the 39 quinolone-resistant isolates showed 38 different ERIC profiles while only two isolates (Pa16 and Pa17) had identical profiles. These heterogeneous ERIC profiles suggest that different strains of *Pseudomonas* spp. were introduced into hospital settings, indicating poor adherence to infection control measures during the study period.

Fifth, one of the strengths of this study wat that it focused on strains that were already resistant to at least one of the quinolones/fluoroquinolones. In contrast, one of the limitations of this study is that we investigated the possible role of PMQR but did not investigate the possible role of chromosomally-mediated resistance mechanisms, which may be mediated by either overexpression of active efflux pumps and/or mutations in QRDR. This is currently under investigation.

In conclusion, PMQR among clinical *Pseudomonas* isolates recovered from Taif in the western region of the KSA is mainly mediated by *qnrD, qnrS*, and *aac(6´)-Ib-cr*. Co-existence of more than one PMQR gene could be responsible for the high-level of fluoroquinolone resistance and horizontal spread of quinolone-resistance can lead to reduced therapeutic options for infections caused by *Pseudomonas* spp. This study increases our understanding of how *Pseudomonas* spp. resist quinolones, which could contribute to better management of patients that acquire nosocomial infections of this bacterium in the KSA.
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[^1]: **Abbreviations:** ERIC, Enterobacterial repetitive inter-genic consensus; qnr, quinolone resistance gene; acc(6ʹ)-Ib-cr, aminoglycoside acetyl transferase-ciprofloxacin variant; Qep, quinolone efflux pump.

[^2]: **Abbreviations:** NT, not tested; NAL; Nalidixic acid, CIP; Ciprofloxacin, NOR; Norfloxacin, OFL; Ofloxacin, GEM; Gemifloxacin, LEV; Levofloxacin, MOX; Moxifloxacin; PMQR, plasmid-mediated quinolone resistance.
